Alternatives to Evidex

DNAnexus Apollo™, accelerates precision drug discovery through collaboration that draws critical insights from omics data. Precision drug discovery requires the collection and analysis of large volumes of clinical and omics data. These data sets are extremely rich, but many legacy and home-grown informatics tools cannot handle their complexity and size. Silos, insufficient collaboration tools, and complex regulatory and security requirements can all hinder precision medicine programs. DNAnexus Apollo™, which supports precision drug discovery programs, empowers scientists and clinicians to analyze and explore omics and clinical data in a single environment built on a robust and scalable cloud platform. Apollo allows them to share data, tools and analyses securely with peers and colleagues from all over the world, regardless of whether they are on another floor or another continent.

All-in-One LIMS, ELN, QMS, and DMS Platform Xybion LIMS is an all-inclusive Digital Laboratory system including LIMS, ELN, QMS, and DMS that creates optimized workflows for the unique business needs of all regulated laboratories including research, diagnostics, quality control, stability studies, and more. Xybion LIMS instills consistency, improves data quality, and supports regulatory compliance with a complete laboratory management solution that connects with your operating systems with powerful laboratory information management and analytics.

BIOiSIMTM, a revolutionary 'virtual drug engine', is the first-in-class tool that allows drug developers to narrow down the number drugs that have potential value in treating or curing specific diseases or illnesses. We offer a variety of translational-based solutions that can be customized for your clinical and pre-clinical programs. All of these solutions are based on our BIOiSIMTM platform, which is a proven and validated platform for small molecules, large molecule, and viruses. Our models are built using data from thousands upon thousands of compounds across seven species, which gives them a robustness that is rare in the industry. The platform is focused on human outcomes and has at its core a translatability tool that transforms insights across species. The BIOiSIMTM platform is available before preclinical animal trials begin, which allows for earlier insights and saves on expensive outsourced experimentation.

adWATCH – AE assists pharmaceutical companies to report adverse events that may occur during clinical trials. adWATCH – AE provides a quick and efficient way for a reporter at a clinic or hospital to generate and manage Adverse Event Reports (AERs), and report to regulatory agencies and government agencies. A negative or dangerous effect is one that a patient experiences due to the use of drugs or medical devices. Adverse event reporting involves the tracking of all medical complaint cases. This allows for the generation of MedWatch reports, CIOMS and additional reports for management. adWATCH – AE allows researchers, physician-investigators, Contract Research Organizations, clinical trial specialists, and other healthcare professionals to create and file AERs in FDA mandated MedWatch or CIOMS format.

Kanteron Platform ingested digital pathology slides, medical images, and patient data from modalities and sequencers. It then provided a complete data toolkit for all hospital network teams. Precision Medicine at the point-of-care: Pharmacogenomics is used to prevent adverse medication events. It also incorporates data sources that have drug-gene interactions that were not previously available in easily accessible formats (e.g. Tables in a PDF document) and implementing the major Pharmacogenomic Databases (like PharmGKB or DGIdb, OpenTargets ...). This allows the user to refine their query to specific gene families, types, interactions, etc. Flexible AI allows you to choose the data set that is most appropriate for your use case and then apply it to your relevant medical images.

Scitara DLX™ provides a fast connectivity infrastructure for any instrument used in life science laboratories. It is fully compliant and auditable, and can be accessed from any cloud-based platform. Scitara™, a universal digital data network, connects all instruments, resources, apps, and software within the laboratory. The cloud-based platform, which is fully auditable, connects all data sources in the lab, allowing data to flow freely across multiple endpoints. Scientists can now spend their time on scientific research and not waste it trying to solve data problems. DLX corrects and curates flight data to support the creation of precise, structured data models that feed AI/ML systems. This supports a successful digital transformation strategy for the pharma and biopharma sectors. The ability to access scientific data allows for faster decision-making and drug discovery, which helps bring drugs to market quicker.

R&D and manufacturing labs must be able to change and reconfigure on the fly in order to accelerate new discoveries and bring products to market quickly. Data management shouldn't be a problem. Thermo Scientific™, Nautilus LIMS™, for Dynamic Discovery and R&D Environments was developed in partnership with customers. It is highly configurable and flexible. It increases workflow efficiency, throughput, data reliability, and simplifies administration, sample traceability, and regulatory compliance.

BC platforms uses the latest science, unique technology capabilities and strategic partnerships to accomplish our mission of revolutionizing drug discovery, personalizing care, and transforming medicine. Modular, flexible platform that integrates healthcare data. Open analytics framework seamlessly combines the most innovative methods, technology developments and analytics in one platform. Superior security: ISO 27001 certified and GDPR and HIPAA compliant. A complete product portfolio allows modern healthcare systems to fully embrace personalized medicine. Scalable deployments allow for a robust start and large-scale healthcare operation. Our unique toolbox enables faster translation of research insights into clinical practice. Our unique toolbox helps reduce risk, increase your pipeline value, and advance enterprise data strategy. We remove the barriers to data access and enable rapid insight generation.

CDD Vault allows you to intuitively organize chemical structures, biological study data, as well as collaborate with external or internal partners via a simple web interface. Start a free trial to see how easy it can be to manage drug discovery data. Tailored for You Affordable Scales with your project team Activity & Registration * Electronic Lab Notebook * Visualization * Inventory * APIs

We are a biotechnology company in clinical stage. We decode biology by integrating technological innovations across biology and chemistry to industrialize drug discovery. CRISPR genome editing and synthetic Biology allow for greater control over biology. Advanced robotics allows for reliable automation of complex laboratory research on an unprecedented scale. Neural network architectures allow for iterative analysis and inference from large, complex, in-house data sets. Cloud solutions increase the flexibility of high-performance computation. To build a next-generation biopharmaceutical business, we are using new technology to create virtuous learning cycles around datasets. A synchronized combination hardware, software, and data that is used to industrialize drug discovery. Redefining the traditional drug discovery process. One of the most extensive, broadest, and deepest pipelines in any technology-enabled drug company.

A series of carefully planned experiments can help you discover biological biomarkers, uncover disease mechanisms, find new drugs, or identify protein levels changes. It's easy to unlock the power of MS/Proteomics. This allows you to focus on the biological complexity and get closer to the moment for discovery. Our automated, repeatable workflow makes it easier to start experiments and reduce turnaround times. This gives you the flexibility and control to make decisions and act on them immediately. Our proteomics data processing workflow allows you to concentrate on biological insights and human to human collaboration. It is built to scale repeatedly. We have made repetitive and heavy processing easy to use the cloud, making it a seamless and enjoyable experience. Intelligent Proteomics seamlessly integrates complex moving parts to allow larger experiments to be processed, analyzed, and reported with ease.

Eidogen-Sertanty’s Target Informatics platform (TIP), is the first global structural informatics system. It enables researchers to examine the druggable genome from an structural perspective. TIP increases the rapidly expanding body experimental protein structure information and transforms structure based drug discovery from an inefficient, data-scarce discipline to a high-throughput science with rich data. TIP is a tool that bridges the knowledge gap between bioinformatics (bioinformatics) and cheminformatics. It provides drug discovery researchers with a knowledge bank of information that is both unique and highly complementary to existing bio- and cheminformatics platform information. TIP's seamless integration between structural data management technology and unique target-to-lead analysis capabilities enhances every stage of the discovery pipeline.

Preclinical information is found in many laboratories. It can be stored in multiple systems within the laboratory and with several external partners. Team members are unable to have clear and informed decisions without a unified solution because they lack transparency in core business data. Pristima, a fully integrated digital laboratory execution platform, features intelligent workflows, task automation, and data and information management throughout the entire preclinical process. Xybion's preclinical platform provides a central data repository as well as a standard archive platform. This platform can help you increase productivity and lower costs. With complete transparency across all platforms, gain visibility into the information that is there and take actions based on your current business needs. Effective data management can reduce the time it takes to submit final SENDs from end-of-study.

Polly allows you to harness the power of biomedical information. The Polly Platform allows you to scale batch jobs, workflows and visualization applications. Polly supports resource pooling, optimizes resource allocation based upon your usage requirements, and makes use of spot instances when possible. This results in optimization, efficiency, quicker response time, and lower costs for resources. Access a dashboard that allows you to monitor and track resource usage and costs in real-time. This will allow you to reduce overheads when resource management is done by your IT team. Polly's infrastructure is built around version control. Polly uses a combination dockers and interactive notebooks to ensure version control for your analyses and workflows. We have created a mechanism that allows data, code, and the environment to co-exist. This, along with cloud data storage and the ability for users to share projects, ensures reproducibility in every analysis.

Global biopharmaceutical drug patents and generic entry business intelligence. Anticipate future budget needs and proactively find generic sources. Examine past successes of patent challengers to identify research paths for competitors. Inform portfolio management decisions on future drug development. Predict brand drug patent expiration, identify generic supplier, and prevent overstocking of branded drugs. Get formulation and manufacturing information. Identify final formulators, repackagers and relabelled.

Chemia is a browser-based & cloud-ready ELN platform. Chemia was designed, developed and architected by scientists. It is a platform that allows you to manage, assign, monitor, and track all R&D activities. It allows you to automate your R&D setup and makes it paperless. It saves time (approx. It saves time (approx. 1 hour per scientist) through Cross-functional collaboration. This makes it audit-ready and helps you manage data effectively. Fast retrieval, search, comparative studies, and reconfigurability allow for faster and more appropriate decisions. A system for managing inventory and scheduling information for chemicals and equipment within a laboratory. A system that tracks equipment usage, maintenance logs, and calibration logs. This is essential for efficient lab management and effective working. A system that provides the protocol, and ensures compliance.

Software that will improve safety, traceability and integration of your Pharmacotechnics and Medicines Manufacturing Unit. PharmaSuite is not designed to be used by all pharmacy services. We have broken PharmaSuite into functional modules that allow you to manage different units in the most efficient manner. Management of the Pharmacotechnics and Drug Preparation units (parenteral mixtures). Management of parenteral nutrition.

Rare diseases are often poorly understood and only a small amount of information is available to support drug discovery programs. Healnet, an AI platform that analyzes millions of data points related to drug and disease, helps overcome these challenges. It identifies novel connections that could lead to new treatment options. We can simultaneously run multiple stages at scale by applying frontier technologies throughout the discovery and development process. It's a simple model that can be used by almost all pharmaceutical companies. One disease, one target and one drug. The next generation in drug discovery is AI-powered and parallel. The key three paradigms of drug discovery are combined.

Our reputation as thought leaders in the areas of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology is earned through the success our clients have found through their relationship with us. With over 20 years of experience, we have the ability to translate science into software that is easy to use. We also provide expert consulting support for drug discovery, clinical research, and regulatory submissions.

AI-powered drug discovery is a proven technology. Cerella extracts hidden insights from your drug discovery data to reveal the best compounds and most valuable experiment for your project. It can make confident predictions by accurately filling in the missing values. This is especially useful for expensive downstream experiments, which are impossible to predict using other methods. This allows you to do more with sparse and limited data sets.

InSilicoTrials.com, a web-based platform that allows users to create and simulate computational models and simulations. There are many easy-to-use tools in silico. The platform is primarily for users in the medical device and pharmaceutical industries. In silico tools for medical devices allow computational testing in different biomedical areas such as radiology, orthopedics, and cardiovascular during product development, validation, and design. The platform offers access to in-silico tools for the pharmaceutical industry, which can be used at all stages of drug discovery and development. It also covers a variety of therapeutic areas. The only cloud-platform built on crowdscience makes it easy to access validated models and reduce your R&D expenses. There is a growing list of models that can be used on a pay-per-use basis.

Advanced molecular modeling can transform drug discovery and materials research. Our physics-based computational platform combines differentiated solutions for predictive modelling, data analytics, collaboration, and collaboration to allow rapid exploration of chemical space. Our platform is used by industry leaders around the world for drug discovery and materials science in fields such as aerospace, energy, semiconductors and electronics displays. The platform powers our drug discovery efforts, from target identification through hit discovery to lead optimization. It also powers our research collaborations to create novel medicines for critical public healthcare needs. Our team includes more than 150 Ph.D. scientists. This allows us to invest heavily in R&D.

Artificial Intelligence and RNA sequencing (RNA–seq data) are both a necessity and a way to develop therapeutics that target splicing mistakes. Machine learning allows us to quickly identify new splicing mistakes and design therapeutic compounds to correct them. SpliceCore, our AI platform for RNA therapeutics research, is what we call SpliceCore. This technology platform was specifically designed for the analysis and interpretation of RNA sequencing data. It can identify, validate and test hypothetical drug targets quicker than traditional methods. Our proprietary database of over 5 million potential RNA-splicing errors is the heart of SpliceCore. It is the world's largest database of splicing mistakes and is used to test all RNA sequencing data that is submitted for analysis. Scalable cloud computing allows us to process large amounts of RNA sequencing data efficiently at a higher speed and lower cost, thereby exponentially accelerating therapeutic innovation.

ArgusLab is a program that allows you to molecular model, graphically, and design drugs for Windows operating systems. Although it is becoming a little outdated, it remains very popular. There have been more than 20,000 downloads to date. ArgusLab can be downloaded for free. You don't have to sign anything. If you're teaching a class in which ArgusLab might be useful, you can print as many copies as necessary. You cannot redistribute ArgusLab to other websites or sources. You may link to this website on your own websites, however. ArgusLab is being port to the iPad in a low-key effort. I have also worked with Qt cross-platform development environment to support Mac, Linux, and PC.

Genedata Biologics®, streamlines the discovery of biotherapeutics. This includes bispecifics and ADCs as well as TCRs, CARs-Ts, CARs-Ts, CARs, and AAVs. It integrates all discovery workflows, making it the most popular platform in the industry. This allows you to focus on innovation and is the most widely used. A first-in-class platform that digitalizes biotherapeutic discovery accelerates research. The platform simplifies complex R&D processes by allowing for the creation, tracking, testing, and evaluation of novel biotherapeutics drugs. It can work with any format: antibodies, bi- and multi-specifics as well as ADCs, novel scaffolds, therapeutic proteins, and engineered therapeutic cell line such CAR-T cells and TCRs. Genedata Biologics acts as a central data backbone that integrates all R&D processes. This includes library design, immunizations, selections, panning, molecular Biology, screening, protein engineering and expression, as well as candidate development and manufacturability assessment.

LiveDesign is an enterprise information platform that allows teams to collaborate, design, experiment, analyze, track, and report in one central platform. You can capture ideas and model data. Create and store virtual compounds in a central database. Use advanced models to prioritize new designs. Integrate biological data and model results from federated corporate databases. Use sophisticated cheminformatics for faster analysis and development of compounds. Advanced physics-based methods are combined with machine learning techniques to quickly improve prediction accuracy. Remote team members can collaborate in real-time. You can collaborate with remote team members to share ideas, test, revise, or advance chemical series without losing sight of your work.

You can share clinical and pre-clinical knowledge easily across your organization using a single platform that integrates all the tools you need. Phoenix WinNonlin is the preferred choice for non-compartmental analysis, toxicokinetic modeling, pharmacokinetic, and pharmacokinetic (PK/PD), modeling by more than 6,000 researchers from biopharmaceutical companies and academic institutions. It also includes 11 global regulatory agencies including the US FDA (EMA), PMDA, and more. The Phoenix Platform features population PK/PD modeling using Phoenix NLME and Level 1 correlation via the Phoenix IIVC Toolkit. Validation Suites allow for quick and easy software validation in less than 30 minutes.

Cortellis™, a suite of life science intelligence software solutions, reveals hidden insights in data. This allows you to make better informed decisions throughout the R&D process. We have taken out the tedious work of finding, integrating and analysing data so that you can concentrate on the crucial decisions required to bring your products to market quicker. Cortellis provides unique data analysis that is rich in domain knowledge, industry insight, and therapeutic expertise. This allows you to unlock hidden insights that will allow you to make data-driven decisions that drive innovation. With the most comprehensive and deepest intelligence, you can get precise and actionable answers to specific questions throughout the R&D process. Cortellis is an indispensable part your daily work flow.

metaphactory converts your data into actionable, contextual and consumable knowledge. It also drives continuous decision intelligence. Intuitive interfaces that are intuitive and out-of-the box for searching, browsing, and exploring your Knowledge Graph. It is possible to create custom interfaces using low-code that allow business users to interact with the Knowledge Graph. Start small, iterate often, and add new use cases, data, and users as you go. Low-code platform for building applications and agile knowledge management.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. More than 2 million scientists and 10,000 customers trust Dotmatics to accelerate research and help make the world a healthier, cleaner, and safer place to live.

Our AI engine transforms drug discovery. Our discoveries help create better medicines faster. Our AI-enabled discovery portfolio is co-owned and owned by prominent investors. Atomwise developed a machine-learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small-molecule medicines. People are the key to redefining drug discovery using AI. We are committed to creating the best AI platform possible and using it to transform small-molecule drug discovery. To help drug developers achieve their goals, we have to tackle the most difficult and seemingly impossible targets. We also need to streamline the drug discovery process in order to make it more efficient. The ability to screen trillions of compounds in silica increases the chance of success. Demonstrates exceptional model accuracy, surpassing the challenge of false negatives.

AIDDISON™, a drug discovery software, combines the power and efficiency of artificial intelligence (AI), computer-aided design (CADD), and machine learning (ML) to provide a valuable toolkit that can be used for medicinal chemistry. It is a unified platform that integrates all aspects of virtual screening, including ligand-based design and structure-based design. It also supports methods for in silico lead optimization and discovery.

Clara's domain specific tools, AI pretrained models, accelerated applications, and accelerated AI applications are enabling AI advances in many fields, including medical device, imaging, drug discovery and genomics. Holoscan allows you to explore the entire pipeline of medical device deployment and development. With the NVIDIA IGX Developer Kits, you can build containerized AI apps using the Holoscan SDK. The NVIDIA IGX SDK includes pre-trained AI model, healthcare-specific acceleration libraries and reference applications for medical devices.

To meet ICH M7 guidelines, predict genotoxic and carcinogenic endpoints for impurities and degradations. Impurity profiling Suite is a tool that can be used in your ICH M7 workflow to help you prepare regulatory submissions and stay compliant.

AutoDock is a set of automated docking tools. It predicts how small molecules, such sub- or drug candidates, will bind to a receptor with a known 3D structure. It has been improved over the years to add new functionalities and multiple engines were developed. AutoDock 4 is the current version, and AutoDock Vina is the latest. AutoDock-GPU is an accelerated version that runs hundreds of times faster than the original single CPU docking code. AutoDock 4 is actually composed of two main programs. Autodock docks the ligand to a list of grids that describe the target protein. Autogrid pre-calculates the grids. The atomic affinity grids can also be visualized. This can be used to help organic synthetic chemists create better binders.

BioNeMo, an AI-powered cloud service for drug discovery and framework, is built on NVIDIA NeMo Megatron. It is used to train and deploy large biomolecular Transformer AI models at supercomputing scale. The service provides pre-trained large language models (LLMs), native support for common file types for proteins, DNA, and chemistry, as well as data loaders for SMILES molecular structures and FASTA amino acid and nucleotide sequencings. You can also download the BioNeMo framework to run on your own infrastructure. ESM-1, which is based on Meta AI’s state-of the-art ESM-1b and ProtT5 respectively, are transformer-based protein-language models that can be used for learning embeddings for tasks such as property prediction and protein structure. BioNeMo will offer OpenFold, a deep-learning model for 3D structure prediction and novel protein sequences.

Metabolon offers the largest Level 1 library available in the metabolomics field. Over 5,400 entries are contained in our proprietary library, which has been built over 20 years. The majority of entries are Level 1, accounting for approximately 85% of our library (4,600 entries). However, some are level 2 (approximately 15 % of the entries), due to a lack commercial standards to qualify for Level 1. Metabolon's unmatched library breadth, industry-leading annotation confidence level and unmatched library depth enable us to provide our clients with accurate, highly actionable insight for their scientific or clinical inquiries. Metabolomics is applicable to a wide variety of research, including soil health, food nutrition, preclinical research and clinical trials. Whether you are looking for trends within a group, or modifying an individual's treatment plan, metabolomics will help you find the answers you need.

Amazon Neptune is a fully managed graph database service that allows you to quickly and reliably build applications that can work with highly connected data sets. Amazon Neptune's core is a purpose-built graph database engine that can store billions of relationships and query the graph with only milliseconds latency. Amazon Neptune supports the popular graph models Property Graph, W3C's RDF, as well as their respective query languages Apache TinkerPop Gremlin, SPARQL. This allows you to quickly build queries that efficiently navigate large datasets. Neptune supports graph use cases like recommendation engines, fraud detection and knowledge graphs. It also powers network security and drug discovery.

We combine clinical and experimental data with machine learning to improve precision medicine and navigate human disease biology. Contingent AI™, a patent-pending technology, understands data relationships to provide sophisticated insights. We tackle data bias by iterating upon machine learning models that are based on decisions made during the feature engineering and pre-processing stages. We use zebrafish, cell, and other phenotypic animals models to validate in-silico predictions in in vivo experiments. We also genetically modify them in vitro to improve translation. We quickly incorporate new data into machine learning models by using active learning and computer vision on validated models of cardiac, central nervous system, and rare disorders.

Makya is a user-friendly SaaS-based platform for AI-driven drug design focusing on Multi-Parametric Optimization. It allows the design of novel compounds that are easy to make in accordance with a multiobjective blueprint at unprecedented speeds, performance and diversity. Makya has multiple generative algorithms that cover different use cases, from hit discovery to lead optimizing: fine-tuning to find optimal solutions in your chemical space according to your project blueprint; novelty to find new ideas of high novelty for rescaffolding/hit discoveries; forward to design a focused collection of compounds easily accessible using commercial starting materials. The new Makya 3D Module enhances the user-experience and scientific utility of Makya. Makya 3D offers a wide range of 3D modeling capabilities in both ligand and structure-based pipelines. You can now use these 3D scores to guide generation natively within Makya.

FCS Express™ gets you from raw data to easily-understandable, beautifully formatted, presentation-ready results more easily and in less time than any other flow cytometry software. You've probably had to copy and paste data tables into another software to make your data more understandable and visually appealing. You've probably had to manage your data in multiple software packages, such as Microsoft Excel™, GraphPad Prism™, or Microsoft Excel™. It was difficult to find everything you needed in one program. Learning flow cytometry software shouldn't be a barrier to getting the best results from your data. FCS Express is designed to look and feel like familiar Microsoft Office™, so you can already be an expert before you even start.

To drive precision medicine programs that work, pharmaceutical companies require comprehensive genomic information. However, decisions are often made with only 10% of the data available. Genomenon provides 100% of the data. ProdigyTM Patient Landscapes are a cost-effective and efficient natural history research solution for pharmaceuticals. They enhance insights from retrospective and prospective health data to support the development rare disease therapies. Genomenon uses an AI-driven approach to deliver a thorough and expert assessment of all patients in the medical literature in a fraction time. Get a complete overview of every genomic biomarker in the medical literature. Every scientific assertion is supported with empirical evidence from medical literature. Identify all genetic drivers and determine which variants are pathogenic according ACMG clinical standards.

Our immunotherapy approach starts with our understanding of antigens. We also know which neoantigens will be present on cells by Human leukocyte antigen molecules. This will allow us to identify the ones that will be transcribed and translated. Gritstone EDGETM is our machine-learning-based platform that enables us to accomplish this. It is difficult to develop cancer immunotherapies that include tumor specific neoantigens. Tumors can have hundreds of mutations. However, only a small number of these mutations result in true tumor-specific antigens. We used EDGE's new integrated neural network architecture to train it with millions of data points from hundreds tumor and normal tissue samples taken from patients of different ancestries.

Genedata Imagence®, allows you to train a deep neural net to classify cellular characteristics in HCS images. This will give you objective, high-quality results. It automates your analysis to allow assay biologists to harness the power of deep learning algorithms. Genedata Imagence allows biologists to immediately and directly analyze HCS imaging data with sophisticated deep learning techniques using no specialized algorithmic knowledge. Don't hide your analysis behind abstract lines of code. Genedata Imagence's intuitive interface makes it easy to QC and explore data at every stage.

DF mSignal is a powerful system that manages signals for drugs, cosmetics and vaccines. It also covers nutraceuticals and food supplements. DF mSignal provides powerful analytics and insights based on product-event combination. This allows for active and passive surveillance. Safety data from multiple regulatory agencies portals and company databases are automatically analyzed to generate statistical scores. Users can monitor potential risks using multi-format data representations and generate signal reports together. DF mSignal is a modular and scalable signal management system which can be integrated into any device. DF mSafety AI as well as other leading safety databases.

ChemDraw®, solutions have been able to provide powerful capabilities and integrations that allow you to quickly transform ideas and drawings into publications you are proud of. ChemOffice+ Cloud is a chemistry communication suite that transforms chemical drawings into chemical knowledge. It facilitates the management, reporting, and presentation of your Chemistry research. ChemOffice+ Cloud is a robust and comprehensive suite that was designed to simplify, facilitate, accelerate, and accelerate chemistry communication. The cloud-native ChemDraw Professional chemistry communication suite adds a powerful set to scientific research by adding a powerful set to the foundations. ChemOffice+ Cloud makes it much easier to create reports to communicate chemical research. Chemists can use ChemOffice+ cloud to create PowerPoint slides and manuscripts that are ready for presentation.

VeraChem LLC was established in 2000 to advance computer-aided drug discovery. These methods are implemented in high-performance software and provide comprehensive support to users. This is a key strategy of VeraChem LLC for product development. Current VeraChem software capabilities include host-guest and protein-ligand binding affinity prediction, fast calculation and computation of partial atomic charges for druglike compounds, computation and force of energies and forces using all the most commonly used empirical force field, automatic generation and generation of alternate resonance forms for drug-like substances, conformational search using the powerful Tork algorithm and automatic detection and removal of topological and 3D-molecular symmetries. VeraChem's software packages were built from a modular code base.

Cloudbyz Safety & Pharmacovigilance Solution, a cloud-based solution, is designed to streamline drug safety and pharmacovigilance for pharmaceutical and life sciences companies. The solution automates the process of collecting data, processing it, analyzing it and reporting it in compliance with global regulations. Cloudbyz provides end-to-end management of the pharmacovigilance lifecycle, including adverse event processing, case management, regulatory reporting, signal detection, and risk management. With Cloudbyz, you can optimize your pharmacovigilance processes, accelerate case processing, and increase the accuracy of your safety data, while minimizing risk and ensuring compliance. The benefits of our solution are listed below- 1. Improved Efficiency with Automation 2. Increased data accuracy 3. Real-time visibility 4. Improved Collaboration 5. Enhanced regulatory compliance

The biopharmaceutical market is complex today. There are growing demands for better specificity and safety, new treatment classes, and more complex mechanisms of disease. To keep up with this complexity, we need to have a better understanding of therapeutic behavior. Simulation and modeling provide unique opportunities to explore biological and physical processes down to the atomic levels. This can be used to guide physical experimentation and accelerate the discovery and development process. BIOVIA Discovery Studio brings together more than 30 years of peer reviewed research and world-class in-silico techniques like molecular mechanics and free energy calculations. It also allows for biotherapeutics developmentability and other related topics into one environment. It gives researchers a complete toolkit to explore the nuances in protein chemistry and to catalyze the discovery of small and big molecule therapeutics, from Target ID to Lead Optimizement.

The process of bringing a new drug to market, from the initial step to the final market introduction can be time-consuming, expensive, and highly regulated. It can take up to a decade. Final success depends on early access to accurate analytical results that are fast enough to make the right decisions during development and minimize late attrition. Today's drug development relies heavily on a rational approach. Typically, identifying the biological target is the first step. To identify the most promising candidates, it is necessary to have a deep understanding about their properties. Finding the most promising lead molecules can be a daunting task once a biological target is established. Lead discovery is typically the identification of potential drug candidates, either small organic molecules or biologic assembly with therapeutic potential.